Kidney360 Publish Ahead of Print, published on July 16, 2021 as doi:10.34067/KID.0000962021 Pkd1 mutation has no apparent effects on peroxisome structure or lipid metabolism Takeshi Terabayashi1, Luis F Menezes1, Fang Zhou1, Hongyi Cai2, Peter J Walter2, Hugo M Garraffo2, Gregory G Germino1 1. Kidney Disease Branch; National Institutes of Diabetes and Digestive and Kidney Disease, NIDDK, National Institutes of Health, Bethesda, MD, United States 2. Clinical Mass Spectrometry Core; National Institutes of Diabetes and Digestive and Kidney Disease, National Institutes of Health, Bethesda, MD, United States Correspondence: Gregory G Germino Kidney Disease Branch; National Institutes of Diabetes and Digestive and Kidney Disease, NIDDK, National Institutes of Health Bethesda, Maryland 20892 United States
[email protected] 1 Copyright 2021 by American Society of Nephrology. Key Points: While fatty acid oxidation defects have been reported in PKD, no studies have examined whether peroxisomes contribute to the abnormalities. We investigated peroxisome biogenesis and FA metabolism in ADPKD models and tested whether polycystin-1 co-localized with peroxisome proteins. Our studies show that loss of Pkd1 does not disrupt peroxisome biogenesis nor peroxisome-dependent FA metabolism. Abstract: Background: Multiple studies of tissue and cell samples from patients and pre-clinical models of autosomal dominant polycystic kidney disease report abnormal mitochondrial function and morphology and suggest metabolic reprogramming is an intrinsic feature of this disease. Peroxisomes interact with mitochondria physically and functionally, and congenital peroxisome biogenesis disorders can cause various phenotypes, including mitochondrial defects, metabolic abnormalities and renal cysts. We hypothesized that a peroxisomal defect might contribute to the metabolic and mitochondrial impairments observed in autosomal dominant polycystic kidney disease.